Observations on carbapenem resistance by minimum inhibitory concentration in nosocomial isolates of acinetobacter species: An experience at a tertiary care hospital in north India

Journal of Health, Population and Nutrition

Volumn 26, Issue 2, 2008, Pages 183-188

  Gaur, A ^a   Garg, A ^a   Prakash, P ^a   Anupurba, S ^a   Mohapatra, T M ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

Acinetobacter; Acinetobacter baumannii; Antibiotic resistance; Carbapenem; Cross infections; Drug resistance; India; Meropenem; Microbial

Indexed keywords

CARBAPENEM DERIVATIVE;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; BACTERIAL INFECTION; CROSS INFECTION; DOSE RESPONSE; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; INDIA; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MULTIDRUG RESISTANCE; TREATMENT OUTCOME;

ACINETOBACTER; ACINETOBACTER INFECTIONS; CARBAPENEMS; COLONY COUNT, MICROBIAL; CROSS INFECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; INDIA; MICROBIAL SENSITIVITY TESTS; TREATMENT OUTCOME;

ACINETOBACTER; ACINETOBACTER BAUMANNII;

EID: 48249091647     PISSN: 16060997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Bergogne-Bérézin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996;9:148-65.
2. Bouvet PJM, Grimont PAD. Taxonomy of the genus Acinetobacter with the recognition of Acinetobacter baumannii sp. nov., Acinetobacter haemolyticus sp. nov., Acinetobacter johnsonii sp. nov., Acinetobacter junii sp. nov., and emended descriptions of Acinetobacter calcoaceticus and Acinetobacter lwoffii. Int J Syst Bacteriol 1986;36:228-40.
3. Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, Rahal JJ. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448-51.
4. Bou G, Cerveró G, Domínguez MA, Quereda. C, Martínez-Beltrán J. Characterization of a nosocomial outbreak caused by a multiresistant Acinetobacter baumannii strain with a carbapenem-hydrolyzing enzyme: high-level carbapenem resistance in A. baumannii is not due solely to the presence of beta-lactamases. J Clin Microbiol 2000;38:3299-305.
5. Sinha M, Srinivasa H. Mechanisms of resistance to carbapenems in meropenem resistant Acinetobacter isolates from clinical samples. Indian J Med Microbiol 2007;25:121-5.
6. Acar JF, Goldstein FW. Consequences of increasing resistance to antimicrobial agents. Clin Infect Dis 1998;27(Suppl 1):S125-S30.
7. Baron EJ, Peterson LR, Finegold SM. Genus Acinetobacter. In: Non-fermentative Gram-negative bacilli and coccobacilli. Bailey and Scott's diagnostic microbiology. 9th ed. St. Louis, MO: Mosby, 1994:401-2.
8. Larson E. A decade of nosocomial Acinetobacter. Am J Infect Control 1984; 12:14-8.
9. Struelens MJ, Carlier E, Maes N, Serruys E, Quint WG, van Belkum A. Nosocomial colonization and infection with multiresistant Acinetobacter baumannii: outbreak delineation using DNA macrorestriction analysis and PCR-fingerprinting. J Hosp Infect 1993; 25:15-32.
10. Prashanth K, Badrinath S. In vitro susceptibility pattern of acinetobacter species to commonly used cephalosporins, quinolones and aminoglycosides. Indian J Med Microbiol 2004;22:97-103.
11. Kucukates E, Kocazeybek B. High resistance rate against 15 different antibiotics in aerobic gram-negative bacteria isolates of cardiology intensive care unit patients. Indian J Med Microbiol 2002;20:208-10.
12. Anstey NM, Currie BJ, Withnall KM. Community-acquired Acinetobacter pneumonia in the Northern Territory of Australia. Clin Infect Dis 1992;14:83-91.
13. Singh AK, Sen MR, Anupurba S, Bhattacharya P. Antibiotic sensitivity pattern of the bacteria isolated from nosocomial infections in ICU. J Commun Dis 2002;34:257-63.
14. Taneja N, Maharwal S, Sharma M. Imipenem resistance in nonfermenters causing nosocomial urinary tract infections. Indian J Med Sci 2003;57:294-9.
15. Aubert G, Guichard D, Vedel G. In-vitro activity of cephalosporins alone and combined with sulbactam against various strains of Acinetobacter baumannii with different antibiotic resistance profiles. J Antimicrob Chemother 1996;37:155-60.
16. Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). [i J Antimicrob Chemother 2002;49:479-87.
17. Manikal VM, Landman D, Saurina G, Oydna E, Lal H, Quale J. Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis 2000;31:101-6.
18. Corbella X, Montero A, Pujol, M, Dominguez MA, Ayats J, Argerich MJ et al. Emergence and rapid spread of carbapenem resistance during large and sustained hospital outbreak of multiresistant Acinetobacter baumannii. J Clin Microbiol 2000;38:4086-95.
19. Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994;344:1329-32.
20. Merz LR, Warren DK, Kollef MH, Fraser VJ. Effects of an antibiotic cycling program on antibiotic prescribing practices in an intensive care unit. Antimicrob Agents Chemother 2004;48:2861-5.
21. Livermore DM. The impact of carbapenemases on antimicrobial development and therapy. Curr Opin Investing Drugs 2002;3:218-24.
22. Poirel L, Nordmann P. Acquired carbapenem-hydrolyzing beta-lactamases and their genetic support. Curr Pharm Biotechnol 2002;3:117-27.